DETERMINE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS & INFECTIONS

确定艾滋病定义并发症的发展时间

• 批准号: 7375194
• 负责人: THOMAS C MERIGAN
• 金额: $ 1.33万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375194
• 关键词: DETERMINE; TIME; DEVELOPMENT; AIDS; DEFINING

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Determine the overall rates of and risk factors for AIDS-defining complications and serious bacterial infections in subjects in the parent study, ACTG 362. Secondary 1. Determine the overall rates and risk factors (e.g. triglycerides, cholesterol, waist-to-hip ratio) for the development of cardiovascular disease in the study cohort. Cardiovascular events of interest include: myocardial infarction, coronary artery revascularization procedures, angina, sudden cardiac death, and stroke. 2. Compare the time to development of AIDS-defining complications and serious infections or cardiovascular disease in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 3. Evaluate the association between CD4 counts and HIV RNA levels at baseline and during follow-up and risk of opportunistic infections and other HIV-related complications. 4. Compare mortality in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 5. Define the risk of cognitive deterioration in a cohort of patients who have been severely immunosuppressed and recovered CD4 counts while taking Highly Active Antiretroviral Therapy (HAART). 6. Identify immunologic (CD4 counts) and virologic (plasma HIV RNA levels) markers and specific drugs (especially PIs) associated with cognitive decline. 7. Evaluate factors associated with long-term adherence to antiretroviral medications and the effect of adherence on viral suppression over time and on the development of opportunistic and serious bacterial infections and cardiovascular disease.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。主要确定父母研究受试者中定义艾滋病并发症和严重细菌感染的总体率和危险因素的总体率和危险因素，ACTG 362。次要1。确定研究队列中心血管疾病发展的总体率和危险因素（例如甘油三酸酯，胆固醇，腰围比）。感兴趣的心血管事件包括：心肌梗塞，冠状动脉血运重建手术，心绞痛，心脏死亡和中风。 2。将被指派接受阿奇霉素的受试者的定义并发症和严重感染或心血管疾病的时间与被分配接受安慰剂的人的时间进行比较。 3。评估基线时CD4计数与HIV RNA水平之间的关联，在机会性感染和其他与HIV相关并发症的随访和风险中。 4。将被分配接受阿奇霉素的受试者与被分配接受安慰剂的人进行比较。 5。定义在接受高度活跃的抗逆转录病毒疗法（HAART）的同时受到严重免疫抑制和恢复计数的患者的认知恶化风险。 6.确定与认知下降有关的免疫学（CD4计数）和病毒学（血浆HIV RNA水平）和特定药物（尤其是PI）。 7.评估与长期遵守抗逆转录病毒药物有关的因素，以及随着时间的流逝以及对机会性和严重细菌感染和心血管疾病的发展的粘附对病毒抑制的影响。